公开(公告)号：US12128060B2

公开(公告)日：2024-10-29

申请号：US17842042

申请日：2022-06-16

Applicant: Elysium Health, Inc.

Inventor： Ryan Dellinger ,  Santiago Roel Santos ,  Eric A. Marcotulli ,  Daniel A. Alminana ,  Mark Morris ,  Leonard Pershing Guarente

IPC: A61K31/706 ,  A61K9/00 ,  A61K31/09 ,  A61P1/16

CPC classification number: A61K31/706 ,  A61K9/0053 ,  A61K31/09 ,  A61P1/16

Abstract: Provided herein are methods and compositions related to treating and/or preventing liver related diseases and disorders and for improving liver health in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside and/or pterostilbene.

公开(公告)号：US20240299501A1

公开(公告)日：2024-09-12

申请号：US18118120

申请日：2023-03-06

Applicant: Xygenyx Inc.

Inventor： Alexy Goldstein

IPC: A61K38/27 ,  A61K9/70 ,  A61K31/05 ,  A61K31/09 ,  A61K36/61

CPC classification number: A61K38/27 ,  A61K9/7023 ,  A61K31/05 ,  A61K31/09 ,  A61K36/61

Abstract: A composition an aqueous gel made up of therapeutically effective amounts of a hormone supplement, β-Caryophyllene, cannabidiol, eucalyptol, menthol, one or more salicylic glycosides, and 2,5-Dimethoxy-p-cymene. The hormone supplement is made up of either homeopathic somatropin or L-DOPA, or both.

公开(公告)号：US20240165039A1

公开(公告)日：2024-05-23

申请号：US18421298

申请日：2024-01-24

Applicant: Bayer Healthcare LLC

Inventor： Javier ZUMETA PEREZ ,  Blanca ALVAREZ MALUENDA ,  Maria Pilar SANZ SAIZ ,  Maria Elena IGLESIAS PIÑEIRO ,  Anthony BELL ,  Reinhard WALTER

IPC: A61K9/48 ,  A61K31/09 ,  A61K31/137 ,  A61K31/167 ,  A61K31/4402 ,  A61K31/485

CPC classification number: A61K9/4825 ,  A61K9/4866 ,  A61K9/4883 ,  A61K31/09 ,  A61K31/137 ,  A61K31/167 ,  A61K31/4402 ,  A61K31/485

Abstract: The present disclosure provides for suspension-based pharmaceutical formulations for cold and flu medications, specifically suspension formulations and soft gel capsule dosage forms having reduced size. The present disclosure also provides methods of preparing the suspensions and soft gel capsule dosage forms.

公开(公告)号：US20240131054A1

公开(公告)日：2024-04-25

申请号：US18382179

申请日：2023-10-19

Applicant: Graceful Caring Hands, Inc.

Inventor： Olukunle Jacob Adebiyi

IPC: A61K33/00 ,  A61K9/00 ,  A61K9/08 ,  A61K31/09 ,  A61K31/495 ,  A61P11/02 ,  A61P11/04

CPC classification number: A61K33/00 ,  A61K9/0043 ,  A61K9/0056 ,  A61K9/0095 ,  A61K9/08 ,  A61K31/09 ,  A61K31/495 ,  A61P11/02 ,  A61P11/04

Abstract: A dosing regimen for administering a composition to a patient for treatment of congestion or irritation includes administering a first dose of the composition to the patient. The composition is formulated as an aqueous solution including between about 0.125 to about 1 milliequivalents of sodium bicarbonate per milliliter of the aqueous solution. The first dose includes between about 0.25 to about 1 milliliter of the composition. The dosing regimen also includes administering a second dose of the composition to the patient after administration of the first dose. The second dose includes between about 0.25 to about 1 milliliter of the composition.

公开(公告)号：US20240130982A1

公开(公告)日：2024-04-25

申请号：US18393055

申请日：2023-12-21

Applicant: Katholieke Uniersiteit Leuven

Inventor： Yicheng NI

IPC: A61K31/09 ,  A61K9/00 ,  A61K31/42 ,  A61K31/661 ,  A61P35/00

CPC classification number: A61K31/09 ,  A61K9/0019 ,  A61K31/42 ,  A61K31/661 ,  A61P35/00 ,  A61K31/122

Abstract: The invention relates to vascular disrupting agent (VDA) such as combretastatins for treating avascular or hypo vascular micro-tumors with a diameter below 20 mm.

公开(公告)号：US20240082356A1

公开(公告)日：2024-03-14

申请号：US18465972

申请日：2023-09-12

Applicant: Therapeutic Solutions International, Inc.

Inventor： Thomas E. ICHIM ,  Timothy G. DIXON ,  James VELTMEYER

IPC: A61K38/19 ,  A61K31/09 ,  A61K35/28 ,  A61P11/00

CPC classification number: A61K38/193 ,  A61K31/09 ,  A61K35/28 ,  A61P11/00

Abstract: Disclosed are means of inducing pulmonary regeneration and/or protection from oxidative stress by stimulation of endogenous stem cell mobilization together with one or more inhibitors of NF-kappa B and/or one or more inhibitors of oxidative stress. The invention discloses the unexpected finding that G-CSF administration enhances oxidative stress and pulmonary damage, however, coadministration with pterostilbene, results in synergistic suppression of COPD pathology.

公开(公告)号：US11911478B2

公开(公告)日：2024-02-27

申请号：US17114104

申请日：2020-12-07

Applicant: Johnson & Johnson Consumer Inc.

Inventor： Gerard P. McNally ,  Anurag Pandey ,  Vipul Dave

IPC: A61K47/38 ,  A61P11/14 ,  A61P11/04 ,  A61K9/08 ,  A61K47/10 ,  A61K47/34 ,  A61P11/00 ,  A61K31/09 ,  A61K31/137 ,  A61K31/167 ,  A61K31/192 ,  A61K31/485 ,  A61K47/26 ,  A61K47/32

CPC classification number: A61K47/38 ,  A61K9/08 ,  A61K31/09 ,  A61K31/137 ,  A61K31/167 ,  A61K31/192 ,  A61K31/485 ,  A61K47/10 ,  A61K47/26 ,  A61K47/32 ,  A61K47/34 ,  A61P11/00 ,  A61P11/04 ,  A61P11/14

Abstract: Compositions useful in the treatment of cough and cold symptoms, including but not limited to, cough, nasal congestion and sore throat, are disclosed.

公开(公告)号：US11890267B2

公开(公告)日：2024-02-06

申请号：US17573333

申请日：2022-01-11

Applicant: Tris Pharma Inc.

Inventor： Andrea Nelson ,  Quin-Zene Chen ,  Harsh Mehta ,  Yu-Hsing Tu

IPC: A61K9/20 ,  A61K31/245 ,  A61K9/00 ,  A61K9/24 ,  A61K9/28 ,  A61K31/09 ,  A61K31/25 ,  A61K45/06 ,  A61K9/50

CPC classification number: A61K31/245 ,  A61K9/0053 ,  A61K9/2009 ,  A61K9/209 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/2886 ,  A61K31/09 ,  A61K31/25 ,  A61K45/06 ,  A61K9/2013 ,  A61K9/5084 ,  A61K31/245 ,  A61K2300/00 ,  A61K31/09 ,  A61K2300/00

Abstract: A modified release benzonatate solid tablet or capsule is described which comprises a benzonatate adsorbate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay.

公开(公告)号：US20240016821A1

公开(公告)日：2024-01-18

申请号：US18351368

申请日：2023-07-12

Applicant: Hygia Pharmaceuticals, LLC

Inventor： Barbara Brooke JENNINGS

IPC: A61K31/6615 ,  A61K9/00 ,  A61K31/352 ,  A61K45/06 ,  A61K47/22 ,  A61K47/12 ,  A61K47/26 ,  A23L33/00 ,  A23L2/52 ,  A61K31/047 ,  A61K31/09 ,  A61K31/661

CPC classification number: A61K31/6615 ,  A61K9/0095 ,  A61K31/352 ,  A61K45/06 ,  A61K47/22 ,  A61K47/12 ,  A61K47/26 ,  A23L33/40 ,  A23L2/52 ,  A61K31/047 ,  A61K31/09 ,  A61K31/661 ,  A23V2002/00

Abstract: A drink product having pharmaceutical compositions as an active ingredients of, at least one phosphorylated inositol, optionally Genistein, optionally Ubiquinol, and optionally additional unphosphorylated inositol. Uses for prevention, treatment, and reduction in risk of developing or progression of a number of conditions are disclosed.

公开(公告)号：US20230310311A1

公开(公告)日：2023-10-05

申请号：US18194840

申请日：2023-04-03

Applicant: The Johns Hopkins University

Inventor： Katharina Maisel ,  Craig W. Hendrix ,  Laura Ensign ,  Edward Fuchs ,  Richard Cone ,  Justin Hanes

IPC: A61K9/00 ,  A61K8/90 ,  A61K9/51 ,  A61K31/09 ,  A61K31/365 ,  A61K47/10 ,  A61K31/352 ,  A61K9/06 ,  A61K31/52 ,  A61K31/675

CPC classification number: A61K9/0031 ,  A61K8/90 ,  A61K9/0034 ,  A61K9/06 ,  A61K9/5146 ,  A61K9/5153 ,  A61K31/09 ,  A61K31/352 ,  A61K31/365 ,  A61K31/52 ,  A61K31/675 ,  A61K47/10 ,  A61K9/08

Abstract: Hypotonic microbicidal compositions including an antimicrobial, such as an antiviral compound, and a pharmaceutically acceptable carrier in a solution formulation having hypotonic osmolarity have been developed for administration rectally to the gastrointestinal mucosa. In a preferred embodiment for use in preventing or decreasing HIV infection, the microbicidal is tenofovir, or a prodrug or derivative thereof. The formulations may include additional agents such as surfactants to enhance cleansing, buffers, or preservatives. Polymers may be included for osmolarity as well as comfort.